Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + High-Dose ICE in Poor Prognosis Germ Cell Tumors
NCT01966913Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2012
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in germ cell tumor (GCT), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Response at 3 months and Toxicity at 6 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01966913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966913.